Bio

Dylan Dupuis, Ph.D. is a Managing Director, Senior Research Analyst at ROTH MKM covering Biotechnology. Dr. Dupuis brings both buy-side and sell-side experience having joined ROTH MKM from Altium Capital, a healthcare focused LIS hedge fund where he served as a SMID-cap Biotech Analyst. Prior to that, Dr. Dupuis worked at SVB Leerink for two years and was eventually promoted to VP Equity Research, Senior Associate helping to cover immunology, inflammatory and metabolic diseases. Dr. Dupuis also served as a Research Associate at B. Riley FBR helping to cover SMID-cap Biotech, and as a trader and assistant branch manager at Seven Points Capital, LLC.

Dr. Dupuis received his Ph.D. in Molecular Biology from Lehigh University focused on A-to-I RNA editing and completed a Post-Doctoral Research Fellowship at the Center for Vascular Biology Research at Beth Israel Deaconess Medical Center, Harvard Medical School. He received his B.S. in Biology and Chemistry from Lycoming College.